ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Exploratory evaluation of CA 15-3 × NLR score for predicting pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the predictive role of the CA 15-3 × neutrophil-to-lymphocyte ratio (NLR) score in estimating pathologic complete response (pCR) in patients with invasive breast cancer who underwent neoadjuvant chemotherapy (NACT).
methodsA total of 330 patients treated with NACT between January 2015 and March 2025 were retrospectively analyzed. The CA 15-3 × neutrophil-to-lymphocyte ratio (NLR) score was calculated by multiplying pre-treatment serum CA 15-3 levels with the NLR. pCR was defined as the absence of invasive carcinoma in both the breast and axillary lymph nodes after surgery. Logistic regression analyses were performed to identify independent predictors of pCR, and receiver operating characteristic (ROC) curve analysis was conducted to determine the optimal cutoff value for the composite score.
resultsThe median age of the study population was 48 years. Pathologic complete response was achieved in 42.4% of patients. The median CA 15-3 × NLR score was significantly lower in the pCR group compared to the non-pCR group (21 vs. 24; p = 0.033). ROC analysis revealed an optimal cutoff value of ≤ 32.7 (AUC = 0.568), with 81.05% sensitivity and 33.9% specificity. In multivariate logistic regression analysis, CA 15-3 × NLR ≤ 32.7 remained an independent predictor of pCR (OR 1.931; 95% CI 1.086-3.433; p = 0.025), along with N stage 2 and the absence of perineural invasion.
conclusionThe CA 15-3 × NLR score demonstrates modest prognostic potential in predicting treatment response in breast cancer patients receiving neoadjuvant chemotherapy. While promising, these findings should be interpreted cautiously, and further validation is needed before clinical implementation.
Indexed as
Identifiers
40819344What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.